IRIX - IRIDEX Corporation

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
6.44
-0.07 (-1.08%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close6.51
Open6.51
Bid0.00 x 800
Ask0.00 x 800
Day's Range6.44 - 6.59
52 Week Range4.28 - 9.99
Volume24,713
Avg. Volume22,390
Market Cap85.848M
Beta1.07
PE Ratio (TTM)N/A
EPS (TTM)-1.30
Earnings DateMar 6, 2018 - Mar 12, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est11.00
Trade prices are not sourced from all markets
  • IRIDEX Corporation (NASDAQ:IRIX): What Does It Mean For Your Portfolio?
    Simply Wall St.8 days ago

    IRIDEX Corporation (NASDAQ:IRIX): What Does It Mean For Your Portfolio?

    Anyone researching IRIDEX Corporation (NASDAQ:IRIX) might want to consider the historical volatility of the share price. Volatility is considered to be a measure of risk in modern finance theory. InvestorsRead More...

  • GlobeNewswire12 days ago

    IRIDEX Announces Pricing of Public Offering of Common Stock

    The offering is expected to close on September 18, 2018, subject to customary closing conditions. Gross proceeds to the Company from the offering are expected to be approximately $10,000,000 before deducting the underwriting discount and other offering expenses payable by the Company and excluding any exercise of the underwriters' option.

  • GlobeNewswire12 days ago

    IRIDEX Announces Proposed Public Offering of Common Stock

    IRIDEX Corporation (IRIX) ("IRIDEX" or the "Company"), an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures used to treat sight-threatening eye conditions, today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock in an underwritten public offering. IRIDEX also expects to grant the underwriters for the offering a 30-day option to purchase an additional 15% of the shares of its common stock offered in the public offering.  All of the shares to be sold in the offering are to be sold by IRIDEX. IRIDEX intends to use the net proceeds from the offering for working capital and other general corporate purposes.

  • GlobeNewswire19 days ago

    IRIDEX Announces FDA Clearance to Introduce Updated TruFocus LIO Premiere™ Laser Accessory to the U.S. Market

    The TruFocus LIO Premiere is a light combination and reflection viewing system used with IRIDEX retina laser systems and is worn on the physician’s head. The product combines a laser treatment beam from an IRIDEX laser source with the illumination beam of a binocular indirect ophthalmoscope into a mixed optical beam used by a physician with a handheld ophthalmic examination lens to enter a patient’s pupil and to view and treat a patient’s retina. “We are pleased to again be offering our full portfolio of laser delivery devices to doctors in the U.S.,” said William M. Moore, President and Chief Executive Officer.

  • Thomson Reuters StreetEvents20 days ago

    Edited Transcript of IRIX earnings conference call or presentation 2-Aug-18 9:00pm GMT

    Q2 2018 IRIDEX Corp Earnings Call

  • GlobeNewswire27 days ago

    IRIDEX Cyclo G6™ Laser System for Glaucoma Treatment Used in Majority of Top U.S. Ophthalmology Hospitals

    IRIDEX Corporation (Nasdaq: IRIX), a leading provider of innovative laser systems in ophthalmology, is pleased to announce that the Company’s Cyclo G6 Glaucoma Laser System is used in 35 of the 39 “Best Hospitals for Ophthalmology” as ranked in a recent report by U.S. News and World Report. The Cyclo G6 system is the first in its class designed specifically to treat patients diagnosed with a range of glaucoma disease states. It features the Company’s proprietary MicroPulse® technology, in which a continuous-wave laser beam is chopped into a train of tiny, repetitive, low energy pulses separated by a brief rest period allowing the tissue to cool between laser pulses.

  • Associated Press2 months ago

    Iridex: 2Q Earnings Snapshot

    The Mountain View, California-based company said it had a loss of 28 cents per share. The medical laser company posted revenue of $10.3 million in the period. Iridex expects full-year revenue in the range ...

  • GlobeNewswire2 months ago

    IRIDEX Announces 2018 Second Quarter Results and Raises Full Year 2018 Guidance

    MOUNTAIN VIEW, Calif., Aug. 02, 2018-- IRIDEX Corporation today reported financial results for the second quarter and six months ended June 30, 2018.. Cyclo G6™ product revenue increased approximately ...

  • GlobeNewswire2 months ago

    IRIDEX to Report Second Quarter 2018 Financial Results on August 2, 2018

    MOUNTAIN VIEW, Calif., July 19, 2018-- IRIDEX Corporation today announced the Company will release financial results for the second quarter 2018 after the close of trading on Thursday, August 2, 2018. ...

  • GlobeNewswire3 months ago

    IRIDEX Reaches Milestone of 1000th Cyclo G6 System Shipped

    IRIDEX Corporation (IRIX) today announced that in the second quarter of 2018 it has shipped the 1,000th unit of its Cyclo G6™ Laser System, which utilizes the Company’s proprietary MicroPulse® technology for the treatment of glaucoma. Dr. Ryo Taniguchi, of the Taniguchi Eye Clinic in Japan, Kyoshu Saga Prefecture, was the recipient of the 1,000th system. “MicroPulse Laser therapy is a new and very promising technology in Japan, providing an effective and non-incisional treatment for glaucoma patients with a range of stages of the disease.

  • Should You Buy IRIDEX Corporation (NASDAQ:IRIX) Now?
    Simply Wall St.3 months ago

    Should You Buy IRIDEX Corporation (NASDAQ:IRIX) Now?

    IRIDEX Corporation (NASDAQ:IRIX), a medical equipment company based in United States, led the NasdaqGM gainers with a relatively large price hike in the past couple of weeks. As a smallRead More...

  • Thomson Reuters StreetEvents5 months ago

    Edited Transcript of IRIX earnings conference call or presentation 3-May-18 9:00pm GMT

    Q1 2018 IRIDEX Corp Earnings Call

  • Associated Press5 months ago

    Iridex: 1Q Earnings Snapshot

    On a per-share basis, the Mountain View, California-based company said it had a loss of 31 cents. The medical laser company posted revenue of $9.5 million in the period. Iridex shares have declined 27 ...

  • PR Newswire6 months ago

    Lifshitz & Miller LLP Announces Investigation of BioScrip, Inc., Civitas Solutions, Inc., Iridex Corp., OHR Pharmaceutical, Inc., Overstock.com, Inc., Syneos Health, Inc., Ubiquiti Networks, Inc. and WageWorks, Inc.

    NEW YORK , March 20, 2018 /PRNewswire/ --   BioScrip, Inc. (BIOS) Lifshitz & Miller  announces investigation into possible breaches of fiduciary duties in connection with BioScrip's disclosure that it ...

  • Thomson Reuters StreetEvents7 months ago

    Edited Transcript of IRIX earnings conference call or presentation 8-Mar-18 10:00pm GMT

    Q4 2017 IRIDEX Corp Earnings Call

  • Associated Press7 months ago

    Iridex reports 4Q loss

    On a per-share basis, the Mountain View, California-based company said it had a loss of 44 cents. The medical laser company posted revenue of $10.2 million in the period. For the year, the company reported ...

  • ACCESSWIRE7 months ago

    IRIDEX Corporation to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / March 8, 2018 / IRIDEX Corporation (NASDAQ: IRIX ) will be discussing their earnings results in their Q4 Earnings Call to be held on March 8, 2018, at 5:00 PM Eastern Time. ...

  • PR Newswire7 months ago

    IRIDEX INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Iridex Corp. To Contact The Firm

    NEW YORK , Feb. 27, 2018 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Iridex Corp. ("Iridex" or the "Company") ...